DD01

DD01 is a once-weekly dual GLP-1/glucagon receptor agonist from Neuraly, the metabolic-disease subsidiary of Korean biotech D&D Pharmatech [1]. The Phase 2 trial in MASLD/MASH (NCT06410924) enrolled 67 overweight/obese patients dosed for 48 weeks against placebo, with the primary endpoint a ≥30% drop in liver fat measured by MRI-PDFF (a non-invasive scan that quantifies the percentage of fat in the liver) [2]. The competitive landscape has hardened sharply in 2024-2025: Madrigal's Rezdiffra (resmetirom) is approved [7]; Novo Nordisk's semaglutide hit its Phase 3 ESSENCE primary endpoint (62.9% MASH resolution vs 34.3% placebo at 72 weeks, NEJM 2025) and now has FDA accelerated approval for MASH with moderate-to-advanced fibrosis [4]; Boehringer's survodutide initiated two Phase 3 trials (LIVERAGE NCT06632444, ~1,800 patients) in October 2024 under FDA Breakthrough Therapy designation [3][8]; Merck still holds the Hanmi-licensed efinopegdutide for NAFLD/MASH (Phase 2b head-to-head vs semaglutide) [9]; tirzepatide repurposing continues via SYNERGY-NASH [5]. DD01 is real science from a credible group, but it is showing up to a fight that big pharma has largely won the head-start on.

Novel investigational compound, never approved anywhere. The Phase 2 MASLD/MASH study (NCT06410924) is listed as completed on ClinicalTrials.gov, but topline data have not been peer-reviewed or formally presented at AASLD 2025 (held November 2025) [2]. A prior Phase 1 study in type 2 diabetes and NAFLD (NCT04812262) cleared on safety and pharmacodynamics [6]. No FDA breakthrough, fast track, orphan, or RMAT designations have been disclosed for DD01 - a meaningful gap given that survodutide secured Breakthrough Therapy in September 2024 [3]. D&D Pharmatech is dual-listed on KOSDAQ (ticker 347850) and Nasdaq. As of mid-2026, market cap is approximately 3.15 trillion KRW (~$2.3B USD) - up roughly 591% year-over-year on pipeline optimism - but cash on hand is only ~37.9B KRW (~$28M USD) against ~6.6B KRW debt, a net cash position of ~$23M [10]. A biopsy-endpoint MASH Phase 3 typically runs 1,500-2,000 patients over multiple years and $300M+; D&D cannot self-fund this, so any Phase 3 advancement effectively requires partnering or a substantial financing round.

Two receptors, one molecule. The GLP-1 arm does what Ozempic and Mounjaro do - slow stomach emptying, suppress appetite, boost insulin secretion when glucose is high - which drives weight loss and better blood sugar [4]. The glucagon arm is the interesting part. Glucagon at pharmacologic doses tells the liver to burn its own fat stores and ramps up whole-body energy expenditure, which is exactly what you want when the disease (MASH) is liver overloaded with fat that has started to inflame and scar. MASLD (metabolic dysfunction-associated steatotic liver disease) is the broad spectrum of fatty liver disease; MASH (metabolic dysfunction-associated steatohepatitis) is the inflammatory/scarring subtype within MASLD that drives liver failure and is the actual regulatory target. The bet is that adding glucagon on top of GLP-1 attacks liver fat from two angles: fewer calories in via appetite suppression, more fat burned out via direct hepatic action. The mechanism is well-validated in 2024-2025. Boehringer's survodutide hit 83% MASH resolution without worsening fibrosis at the 6.0 mg dose (vs 18% placebo) and 64.5% fibrosis improvement in F2/F3 patients at 48 weeks in Phase 2 (Sanyal et al., NEJM 2024) - the strongest dataset ever produced in this indication [3]. So the class works. The question for DD01 is purely whether this specific molecule's potency ratio, half-life, and tolerability window match or beat that bar - not whether the biology is real.

NCT06410924 is a Phase 2a, placebo-controlled, multi-dose study with 67 patients dosed for 48 weeks. Primary endpoint is proportion of subjects achieving ≥30% liver fat reduction on MRI-PDFF - a non-invasive imaging readout that correlates with histologic improvement but is not a registrational endpoint [2]. The trial size is small for a metabolic-disease readout: survodutide's key-style Phase 2 enrolled 295 patients, and ESSENCE Part 1 enrolled 800 [3][4]. A 67-patient n is fine for proof-of-concept but won't power any subgroup analysis and leaves wide confidence intervals on the placebo-adjusted response rate. There's no histology in this trial - biopsies are missing. This matters because regulators require biopsy-confirmed endpoints (MASH resolution without worsening fibrosis, and/or fibrosis improvement without worsening MASH) to demonstrate that surrogate fat reduction translates into reduced inflammation and scarring - the outcomes that prevent cirrhosis and liver failure. Even a clean win on MRI-PDFF will require a follow-up biopsy-endpoint study before any registrational path opens. The design tells you Neuraly is de-risking, not registering. Expect topline at AASLD or EASL in 2026; full data publication probably 2026.

About 5 in 100 drugs at this stage in this area ultimately reach approval, and our model estimates this one sits right at that 5% mark. The estimate starts from that historical baseline and then adjusts based on ten specific facts about this trial and its sponsor. The biggest drags on the estimate are the sponsor's thin approval history, weak earlier-phase results, heavier-than-usual blinding, and a randomized trial design. The remaining factors were close to average for this stage, so they left the final number near where it started.

Efficacy risk is the binary. A 67-patient trial with a continuous biomarker endpoint can fail to separate from placebo even when the drug works, especially if dose selection is off. Survodutide and tirzepatide have set the Phase 2 bar that DD01's small trial may not clearly clear. Safety risk is class-specific. The glucagon arm of dual agonists can raise fasting glucose and degrade glycemic control if the GLP-1/glucagon balance is wrong - this killed earlier programs from Zealand and Pfizer. Gastrointestinal tolerability - nausea, vomiting, dose-limiting dropout - has been the binding constraint across the entire GLP-1 class [4]. Execution risk is the dominant near-term concern: D&D Pharmatech's ~$28M cash position [10] cannot fund a biopsy-endpoint Phase 3 (~$300M+ over multiple years). Without a Western big-pharma partner or a major financing round, this program stalls after Phase 2 readout regardless of the data. The high market cap reflects pipeline optimism, not balance-sheet strength. Commercial risk is the killer even if everything works: by the time DD01 could plausibly reach approval (2030+), the MASH market will already include Rezdiffra (approved), semaglutide (FDA accelerated approval as of 2025 with full approval likely), and survodutide (Phase 3 LIVERAGE readout expected ~2027-2028) [4][8]. Late-mover dual agonists need clear differentiation (better tolerability, superior fibrosis response, oral formulation) - none of which DD01 has yet demonstrated.

Watch but don't chase. The signal that matters is the Phase 2 topline - specifically, the placebo-adjusted MRI-PDFF response at the top dose, and the discontinuation rate from GI adverse events. If DD01 hits >30 percentage points of separation with <15% dropout, it becomes a credible partnering asset and D&D Pharmatech's KOSDAQ stock has room to move further - though the 591% YoY run-up [10] means much of the optimism is already priced in. Below that bar, this is a science project with a small-cap stock that has gotten ahead of itself. Check back at AASLD 2026 (the most likely venue, since AASLD 2025 came and went without a DD01 presentation) or for an 8-K-equivalent Korean exchange disclosure. The broader read on D&D Pharmatech matters more than DD01 in isolation - NLY01 missed its primary endpoint in Phase 2 Parkinson's (255 patients, March 2023 readout, Lancet Neurology 2023) and only showed a post-hoc effect in patients under 60 [11]. With one Phase 2 miss already on the platform, a clean DD01 readout becomes existentially important to the company's narrative; a miss likely forces partnership terms or strategic restructuring.